Cayman Chemical

Peptide sequence: human cPGE synthase amino acids 58-67 (CIDPNDSKHK) To be used in conjunction with Cayman’s cPGEsynthase polyclonal antibody (Catalog No. 160150) to block protein-antibody complex formation during analysis for cPGE synthase.

A potent, selective agonist of the neuromedin K3 (NK3) receptor (EC₅₀ = 0.5-3 nM); used to study the action of the NK3 receptor in cells and in animals.

A cell permeable, peptide aldehyde inhibitor of calpain I (Ki = 120 nM), calpain II (Ki = 230 nM), cathepsin B (Ki = 100 nM), and cathepsin L (Ki = 0.6 nM).

An analog of 1,24-dihydroxy vitamin D3 which, when used in a 4 μg/g ointment, suppresses psoriasis; inhibits the growth of both normal and psoriatic human keratinocytes (IC50 ~ 10 nM) via the vitamin D receptor; suppresses the production of RANTES and IL-8 by human dermal fibroblasts.

A selective Aurora kinase inhibitor (IC₅₀s = 5, 4, and 1 nM for Aurora A, B, and C, respectively); inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models.

A structural analog of melatonin that binds the melatonin MT2 receptor (Ki = 41 nM); acts as a melatonin receptor antagonist in frog skin and chicken retina and as a partial agonist in rabbit retina.

An intermediate in the biosynthesis of trehalose.

Cayman’s HAT Inhibitor Screening Assay provides a fast, fluorescence-based method for evaluating PCAF HAT inhibitors. The procedure requires only three easy steps, all performed in the same microplate. In the first step of the protocol, HAT is incubated with acetyl-CoA and the histone H3...

A competitive inhibitor of PFKFB3 (IC₅₀ = 23 µM) that causes a rapid reduction in F2,6BP, glucose uptake, and lactate secretion, resulting in cell cycle arrest in Jurkat cells; markedly reduces intracellular F2,6BP, glucose uptake, and growth of established tumors in mice; also...

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which promote the differentiation of monocytes via the nuclear receptor PPARγ. One of these substances was recently isolated and purified from oxLDL, and identified as azelaoyl PAF. Azelaoyl PAF is a potent...

A natural (ADEP) antibiotic that constitutively activates the bacterial protease ClpP, resulting in uncontrolled proteolysis, inhibition of bacterial cell division, and, ultimately, cell death; preferentially targets Gram-positive bacteria.

A structural analog of SB 202190 and SB 203580 that is used as a negative control in studies of p38 inhibition.

15(S)-15-methyl PGF2α methyl ester is a derivative of 15(S)-15-methyl PGF2α with increased membrane permeability. Hydrolysis of the methyl ester in vivo releases the biologically active 15(S)-15-methyl PGF2α, which is a potent uterine stimulant and abortifacient.

A PDMP mixture containing D-threo (1R,2R) and L-threo (1S,2S) PDMP; reduces the synthesis of glucosylceramide increases cellular ceramide, and induces cell cycle arrest.

A selective Akt inhibitor.

A potent agonist of muscarinic acetylcholine receptors (EC50 values are 0.3, 92.5, 5, 52, and 42 nM for M1, M2, M3, M4, and M5, respectively); has antipsychotic-like activities in rats and Cebus monkeys; enhances memory function and has utility in treating Alzheimer’s Disease.

A plant alkaloid used as starting material for the synthesis of the anticancer antibiotics vinblastine and vincristine.

CAY10493 is a synthetic intermediate useful for pharmaceutical synthesis.

A selective α2-adrenoceptor agonist (Ki = 1.62 nM) that binds to α1-adrenoceptors with much weaker potency (Ki = 415 nM); primarily used as a sedative for horses in large animal veterinary medicine.

An internal standard for the quantification of OEA by GC- or LC-MS.

A procaspase-3 activator and a potential drug treatment in cancer cell lines with elevated levels of procaspase-3; exhibits an IC50 value of 3 nM for induction of cancer cell death without affecting non-cancerous cells.

An internal standard for the quantification of 8,12-iso-iPF2α-VI by GC- or LC-MS.

A selective CB2 receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors (Ki = 400 nM for rat brain and human CB1 receptors).

A pan-caspase inhibitor that blocks apoptosis, prevents the production of cytokines, and inhibits T cell proliferation dose-dependently at 1-100 μM.